Summary of SCICLONE PHARMACEUTICALS INC

Item 2.02. Results of Operations and Financial Condition.

On May 11, 2009, SciClone Pharmaceuticals, Inc. ("SciClone") issued a press release announcing, among other things, financial results for the quarter ended March 31, 2009, as well as revised expectations regarding certain guidance as to 2009 financial results. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein in its entirety.

The information in Item 2.02 of this Current Report, including Exhibit 99.1 to this Current Report, shall not be deemed to be "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by SciClone with the Securities and Exchange Commission, whether made before or after the date of this Current Report, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference to Item 2.02 and the accompanying Exhibit 99.1 in such filing.

Forward-Looking Statements.

The exhibit to this Current Report contains forward-looking statements regarding the business, products and financial results of SciClone Pharmaceuticals, Inc. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These risks and uncertainties include SciClone's expectations regarding fluctuations in demand for its products, particularly in China, the continued reliability of third-party suppliers to meet demand and quality expectations and activity to launch additional products, including DC Bead in China and the potential acquisition or licensing of other products. Please also refer to other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.